The targeted agents used for the therapy of kidney cancer are mainly based on kinase inhibitors such as temsirolimus or everolimus, which act on mTOR, or ample spectrum inhibitors such as sorafenib, and the receptor tyrosine kinase (RTK) inhibitors sunitinib, pazopanib, axitinib, or cabozantinib [3]. This evidence concerns the gene NTRK1 and kidney cancer.